1Department of Cardiology, Mount Sinai Beth Israel Hospital, New York, NY, USA
2Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY, USA
3Albert Einstein College of Medicine, Bronx, NY, USA
4Division of Pulmonary and Critical Care Medicine, Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY, USA
5Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University School of Medicine, Atlanta, GA, USA
6Institute of Critical Care Medicine, Mount Sinai Hospital, New York, NY, USA
7Division of Pulmonary and Critical Care Medicine, Beth Israel Lahey Health, Burlington, MA, USA
8Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Arkansas for Medical Sciences Medical Center, Little Rock, AR, USA
9Department of Obstetrics and Gynecology, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY, USA
Copyright © 2021 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTIONS
Conceptualization: BKJH, RTF, PG. Methodology: BKJH, AK (Adarsh Katamreddy), JSG, JYY, RTF, PG. Formal analysis: BKJH, ASN, AK (Adarsh Katamreddy), JYY, PG. Data curation: BKJH, ASN, OLO, AK (Ankit Kushwaha), AK (Ankita Krishnan), MN. Project administration: BKJH, LP, JM, ST, SM, AG, HG, MS, RTF, PG. Visualization: BKJH, PG. Writing - Original draft: ASN, AK (Adarsh Katamreddy), JSG, JYY, MS, PG. Writing - Review and editing: BKJH, ASN, AK (Adarsh Katamreddy), OLO, AK (Ankit Kushwaha), AK (Ankita Krishnan), MN, LP, JM, ST, SM, AG, HG, MS, RTF, PG. Writing–review & editing: all authors.
Variable | Non-SIC (n=340) | SIC (n=19) | P-valuea |
---|---|---|---|
Age (yr) | 67±16 | 64±18 | 0.412 |
Female sex | 185 (54.4) | 12 (63.2) | 0.541 |
Diabetes mellitus | 137 (40.2) | 11 (57.9) | 0.101 |
Hypertension | 224 (65.9) | 12 (63.2) | 0.803 |
CAD | 58 (17.1) | 4 (21.1) | 0.734 |
History of heart failure | 59 (17.4) | 7 (36.8) | 0.029 |
ESRD | 28 (8.2) | 1 (5.3) | 0.591 |
History of CVA | 78 (22.9) | 3 (15.8) | 0.502 |
COPD | 73 (21.5) | 5 (26.3) | 0.613 |
Cirrhosis | 31 (9.1) | 2 (10.5) | 0.804 |
Beta-blocker use | 128 (38.0) | 9 (47.4) | 0.565 |
APACHE II score | 19 (13.0–24.2) | 22 (18.5–27.5) | 0.016 |
Lactate (mmol/L) | 3.2 (1.8–6.4) | 4.6 (3.0–8.3) | 0.108 |
Troponin T (μg/L) | 0.1 (0.0–0.4) | 0.2 (0.0–1.1) | 0.186 |
Albumin (g/dl) | 3.23±0.76 | 2.57±0.63 | <0.001 |
Echocardiographic parameter | |||
LVEF | 64.0 (58.0–70.0) | 30.0 (20.0–37.5) | <0.001 |
Regional wall motion abnormality | 30 (9.0) | 9 (50.0) | <0.001 |
RV dilation | 23 (7.1) | 2 (13.3) | 0.304 |
RV hypokinesis | 25 (7.4) | 13 (68.4) | <0.001 |
Shock requiring vasopressors | 128 (37.6) | 16 (84.2) | <0.001 |
Mechanical ventilation | 151 (44.4) | 17 (89.5) | <0.001 |
Culture positivityb | 140 (41.1) | 17 (89.5) | <0.001 |
Mortality | 60 (17.6) | 8 (42.1) | 0.008 |
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
SIC: sepsis-induced cardiomyopathy; CAD: coronary artery disease; ESRD: end-stage renal disease; CVA: cerebrovascular accident/transient ischemic accident; COPD: chronic obstructive pulmonary disease; APACHE: Acute Physiology and Chronic Health Evaluation; LVEF: left ventricular ejection fraction; RV: right ventricular.
aP-value for chi-square test (categorial variables: female, diabetes mellitus, hypertension, CAD, history of heart failure, ESRD, CVA, COPD, cirrhosis, regional wall motion abnormality, RV dilation, RV hypokinesis, shock requiring vasopressors, mechanical ventilation, culture positivity, and mortality), ttest (continuous variables: age and albumin), or Kruskal-Wallis test (skewed distribution: lactate, troponin T, and LVEF); significant values P<0.05;
bGrowth of at least one microorganism in body fluids and/or biopsy specimens.
Variable |
Univariable model |
Multivariable model |
||
---|---|---|---|---|
OR (95% CI) | P-valuea | OR (95% CI) | P-valuea | |
Sepsis-induced cardiomyopathy | 4.35 (2.19–8.63) | <0.001 | 4.46 (1.15–18.69) | 0.031 |
Albumin levelb | 0.41 (0.29–0.57) | <0.001 | 0.63 (0.40–0.99) | 0.048 |
APACHE II scorec | 1.77 (1.04–2.27) | <0.001 | 1.11 (0.80–1.58) | 0.503 |
Culture positivityd | 1.81 (1.10–3.01) | 0.022 | 0.84 (0.42–1.64) | 0.612 |
Lactatee | 1.26 (1.18–1.35) | <0.001 | 1.12 (1.13–1.31) | <0.001 |
Shock requiring vasopressors | 7.03 (4.05–12.60) | <0.001 | 1.76 (0.83–3.77) | 0.131 |
Mechanical ventilation | 9.18 (4.98–18.15) | <0.001 | 3.36 (1.52–7.77) | 0.003 |
History of heart failure | 1.29 (0.68–2.36) | 0.407 | ||
Sexf | 1.09 (0.66–1.80) | 0.728 | ||
Ageg | 1.00 (0.99–1.02) | 0.333 | ||
CAD | 1.04 (0.52–1.97) | 0.891 | ||
ESRD | 1.99 (0.85–4.39) | 0.092 | ||
HIV | 0.76 (0.21–2.10) | 0.631 | ||
Troponin Th | 1.00 (0.97–1.02) | 0.844 | ||
Beta-blocker use | 0.66 (0.38–1.11) | 0.132 | ||
History of CVAi | 0.84 (0.35–1.83) | 0.691 | ||
COPD | 1.23 (0.55–2.57) | 0.591 | ||
Cirrhosis | 0.78 (0.18–2.34) | 0.693 | ||
Hypertension | 0.82 (0.49–1.39) | 0.454 | ||
Diabetes mellitus | 1.02 (0.61–1.70) | 0.912 |
OR: odds ratio; CI: confidence interval; APACHE: Acute Physiology and Chronic Health Evaluation; CAD: coronary artery disease; ESRD: end-stage renal disease; HIV: human immunodeficiency virus; CVA: cerebrovascular accident; COPD: chronic obstructive pulmonary disease.
aWald’s chi-square test of β-coefficient in the binary logistic regression model; significant values P<0.05;
bPer one-unit increase in g/dL;
cEvery one-unit increase in APACHE II score;
dGrowth of at least one microorganism in body fluids and/or biopsy specimens;
eLactate per one-unit increase in mmol/L;
fFemale vs. male;
gIn years;
hIn μg/L;
iCVA/transient ischemic accident.
Variable |
Univariable model |
Multivariable model |
||
---|---|---|---|---|
OR (95% CI) | P-valuea | OR (95% CI) | P-valuea | |
Albumin levelb | 0.55 (0.36–0.84) | 0.006 | 0.47 (0.23–0.93) | 0.031 |
History of heart failure | 3.15 (1.53–6.34) | 0.001 | 2.72 (0.87–8.10) | 0.072 |
APACHE II scorec | 1.53 (1.13–2.09) | 0.007 | 1.10 (0.66–1.88) | 0.714 |
Culture positivityd | 3.47 (1.74–7.32) | <0.001 | 8.47 (2.24–55.61) | 0.006 |
Shock requiring vasopressors | 8.91 (2.90–38.87) | <0.001 | 2.23 (0.57–11.39) | 0.271 |
Mechanical ventilation | 10.75 (3.02–68.48) | 0.002 | 4.38 (0.95–32.08) | 0.081 |
Sexe | 1.01 (0.52–1.99) | 0.954 | ||
Agef | 1.01 (0.99–1.03) | 0.212 | ||
CAD | 2.00 (0.90–4.16) | 0.073 | ||
ESRD | 1.75 (0.56–4.56) | 0.284 | ||
HIV | 1.90 (0.53–5.45) | 0.271 | ||
Lactateg | 1.04 (0.98–1.11) | 0.152 | ||
Troponin Th | 0.98 (0.87–1.01) | 0.644 | ||
Beta-blocker use | 1.51 (0.77–2.93) | 0.221 | ||
Diabetes mellitus | 2.03 (0.80–5.39) | 0.143 | ||
Hypertension | 0.89 (0.35–2.46) | 0.821 |
SIC: sepsis-induced cardiomyopathy; OR: odds ratio; CI: confidence interval; APACHE: Acute Physiology And Chronic Health Evaluation; CAD: coronary artery disease; ESRD: end-stage renal disease; HIV: human immunodeficiency virus.
aP-value for Wald’s chi-square test of β-coefficient in the binary logistic regression model; significant values P<0.05;
bPer one-unit increase in g/dl;
cEvery one-unit increase in APACHE II score;
dGrowth of at least one microorganism in body fluids and/or biopsy specimens;
efemale vs. male;
fIn years;
gPer one-unit increase in mmol/L;
hIn μg/L.
Variable | Non-SIC (n=340) | SIC (n=19) | P-value |
---|---|---|---|
Age (yr) | 67±16 | 64±18 | 0.412 |
Female sex | 185 (54.4) | 12 (63.2) | 0.541 |
Diabetes mellitus | 137 (40.2) | 11 (57.9) | 0.101 |
Hypertension | 224 (65.9) | 12 (63.2) | 0.803 |
CAD | 58 (17.1) | 4 (21.1) | 0.734 |
History of heart failure | 59 (17.4) | 7 (36.8) | 0.029 |
ESRD | 28 (8.2) | 1 (5.3) | 0.591 |
History of CVA | 78 (22.9) | 3 (15.8) | 0.502 |
COPD | 73 (21.5) | 5 (26.3) | 0.613 |
Cirrhosis | 31 (9.1) | 2 (10.5) | 0.804 |
Beta-blocker use | 128 (38.0) | 9 (47.4) | 0.565 |
APACHE II score | 19 (13.0–24.2) | 22 (18.5–27.5) | 0.016 |
Lactate (mmol/L) | 3.2 (1.8–6.4) | 4.6 (3.0–8.3) | 0.108 |
Troponin T (μg/L) | 0.1 (0.0–0.4) | 0.2 (0.0–1.1) | 0.186 |
Albumin (g/dl) | 3.23±0.76 | 2.57±0.63 | <0.001 |
Echocardiographic parameter | |||
LVEF | 64.0 (58.0–70.0) | 30.0 (20.0–37.5) | <0.001 |
Regional wall motion abnormality | 30 (9.0) | 9 (50.0) | <0.001 |
RV dilation | 23 (7.1) | 2 (13.3) | 0.304 |
RV hypokinesis | 25 (7.4) | 13 (68.4) | <0.001 |
Shock requiring vasopressors | 128 (37.6) | 16 (84.2) | <0.001 |
Mechanical ventilation | 151 (44.4) | 17 (89.5) | <0.001 |
Culture positivity |
140 (41.1) | 17 (89.5) | <0.001 |
Mortality | 60 (17.6) | 8 (42.1) | 0.008 |
Variable | Univariable model |
Multivariable model |
||
---|---|---|---|---|
OR (95% CI) | P-value |
OR (95% CI) | P-value |
|
Sepsis-induced cardiomyopathy | 4.35 (2.19–8.63) | <0.001 | 4.46 (1.15–18.69) | 0.031 |
Albumin level |
0.41 (0.29–0.57) | <0.001 | 0.63 (0.40–0.99) | 0.048 |
APACHE II score |
1.77 (1.04–2.27) | <0.001 | 1.11 (0.80–1.58) | 0.503 |
Culture positivity |
1.81 (1.10–3.01) | 0.022 | 0.84 (0.42–1.64) | 0.612 |
Lactate |
1.26 (1.18–1.35) | <0.001 | 1.12 (1.13–1.31) | <0.001 |
Shock requiring vasopressors | 7.03 (4.05–12.60) | <0.001 | 1.76 (0.83–3.77) | 0.131 |
Mechanical ventilation | 9.18 (4.98–18.15) | <0.001 | 3.36 (1.52–7.77) | 0.003 |
History of heart failure | 1.29 (0.68–2.36) | 0.407 | ||
Sex |
1.09 (0.66–1.80) | 0.728 | ||
Age |
1.00 (0.99–1.02) | 0.333 | ||
CAD | 1.04 (0.52–1.97) | 0.891 | ||
ESRD | 1.99 (0.85–4.39) | 0.092 | ||
HIV | 0.76 (0.21–2.10) | 0.631 | ||
Troponin T |
1.00 (0.97–1.02) | 0.844 | ||
Beta-blocker use | 0.66 (0.38–1.11) | 0.132 | ||
History of CVA |
0.84 (0.35–1.83) | 0.691 | ||
COPD | 1.23 (0.55–2.57) | 0.591 | ||
Cirrhosis | 0.78 (0.18–2.34) | 0.693 | ||
Hypertension | 0.82 (0.49–1.39) | 0.454 | ||
Diabetes mellitus | 1.02 (0.61–1.70) | 0.912 |
Variable | Univariable model |
Multivariable model |
||
---|---|---|---|---|
OR (95% CI) | P-value |
OR (95% CI) | P-value |
|
Albumin level |
0.55 (0.36–0.84) | 0.006 | 0.47 (0.23–0.93) | 0.031 |
History of heart failure | 3.15 (1.53–6.34) | 0.001 | 2.72 (0.87–8.10) | 0.072 |
APACHE II score |
1.53 (1.13–2.09) | 0.007 | 1.10 (0.66–1.88) | 0.714 |
Culture positivity |
3.47 (1.74–7.32) | <0.001 | 8.47 (2.24–55.61) | 0.006 |
Shock requiring vasopressors | 8.91 (2.90–38.87) | <0.001 | 2.23 (0.57–11.39) | 0.271 |
Mechanical ventilation | 10.75 (3.02–68.48) | 0.002 | 4.38 (0.95–32.08) | 0.081 |
Sex |
1.01 (0.52–1.99) | 0.954 | ||
Age |
1.01 (0.99–1.03) | 0.212 | ||
CAD | 2.00 (0.90–4.16) | 0.073 | ||
ESRD | 1.75 (0.56–4.56) | 0.284 | ||
HIV | 1.90 (0.53–5.45) | 0.271 | ||
Lactate |
1.04 (0.98–1.11) | 0.152 | ||
Troponin T |
0.98 (0.87–1.01) | 0.644 | ||
Beta-blocker use | 1.51 (0.77–2.93) | 0.221 | ||
Diabetes mellitus | 2.03 (0.80–5.39) | 0.143 | ||
Hypertension | 0.89 (0.35–2.46) | 0.821 |
Values are presented as mean±standard deviation, number (%), or median (interquartile range). SIC: sepsis-induced cardiomyopathy; CAD: coronary artery disease; ESRD: end-stage renal disease; CVA: cerebrovascular accident/transient ischemic accident; COPD: chronic obstructive pulmonary disease; APACHE: Acute Physiology and Chronic Health Evaluation; LVEF: left ventricular ejection fraction; RV: right ventricular. P-value for chi-square test (categorial variables: female, diabetes mellitus, hypertension, CAD, history of heart failure, ESRD, CVA, COPD, cirrhosis, regional wall motion abnormality, RV dilation, RV hypokinesis, shock requiring vasopressors, mechanical ventilation, culture positivity, and mortality), ttest (continuous variables: age and albumin), or Kruskal-Wallis test (skewed distribution: lactate, troponin T, and LVEF); significant values P<0.05; Growth of at least one microorganism in body fluids and/or biopsy specimens.
OR: odds ratio; CI: confidence interval; APACHE: Acute Physiology and Chronic Health Evaluation; CAD: coronary artery disease; ESRD: end-stage renal disease; HIV: human immunodeficiency virus; CVA: cerebrovascular accident; COPD: chronic obstructive pulmonary disease. Wald’s chi-square test of β-coefficient in the binary logistic regression model; significant values P<0.05; Per one-unit increase in g/dL; Every one-unit increase in APACHE II score; Growth of at least one microorganism in body fluids and/or biopsy specimens; Lactate per one-unit increase in mmol/L; Female vs. male; In years; In μg/L; CVA/transient ischemic accident.
SIC: sepsis-induced cardiomyopathy; OR: odds ratio; CI: confidence interval; APACHE: Acute Physiology And Chronic Health Evaluation; CAD: coronary artery disease; ESRD: end-stage renal disease; HIV: human immunodeficiency virus. P-value for Wald’s chi-square test of β-coefficient in the binary logistic regression model; significant values P<0.05; Per one-unit increase in g/dl; Every one-unit increase in APACHE II score; Growth of at least one microorganism in body fluids and/or biopsy specimens; female vs. male; In years; Per one-unit increase in mmol/L; In μg/L.